A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Business, Management and Accounting
1
2%
Other
2
4%
Unknown
23
43%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2018.
All research outputs
#21,075,298
of 25,837,817 outputs
Outputs from Gynecologic Oncology
#4,372
of 5,052 outputs
Outputs of similar age
#345,081
of 451,082 outputs
Outputs of similar age from Gynecologic Oncology
#52
of 70 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,052 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,082 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
